The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer.
Sinha, Seema
The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer. [electronic resource] - Cancer discovery 07 2017 - 673-674 p. digital
Publication Type: Journal Article; Comment
2159-8290
10.1158/2159-8290.CD-17-0481 doi
Cell Transdifferentiation--drug effects
Drug Resistance, Neoplasm--genetics
Humans
Male
Prostatic Neoplasms--drug therapy
Receptors, Androgen--drug effects
The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer. [electronic resource] - Cancer discovery 07 2017 - 673-674 p. digital
Publication Type: Journal Article; Comment
2159-8290
10.1158/2159-8290.CD-17-0481 doi
Cell Transdifferentiation--drug effects
Drug Resistance, Neoplasm--genetics
Humans
Male
Prostatic Neoplasms--drug therapy
Receptors, Androgen--drug effects